Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00363467 · ClinicalTrials.gov registry record · NA
Busulfan Monotherapy as Conditioning for Autologous Hematopoietic Progenitor Cell Transplantation
A NA study, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
- Terminated
- Registry status
- NA
- Development phase
- 3
- Enrollment target
NCT00363467: Clinical Trial NA study, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
NCT00363467 is a NA study that was terminated before completion, run by H. Lee Moffitt Cancer Center and Research Institute. The registered enrollment target is 3 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (100% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00363467, a NA study, was terminated before completion, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
- TERMINATED
- Registry status
- NA
- Development phase
- 3 participants
- Enrollment target
Study Summary
During the pre-transplantation phase (following completion of consolidation chemotherapy), patients will begin to receive G-CSF at 10 mcg/kg twice daily; leukapheresis will also be given until a target goal for recipient body weight is obtained, or up to a maximum of 5 days. Conditioning/Preparative therapy will follow PBSC collection for up to 30 days with Busulfan IV daily x 4 days; subsequent doses will be adjusted based on pharmacokinetic (plasma level)monitoring. Following 1 day of rest, stem cell reinfusion will begin with supportive care. During follow-up, patients will be monitored out to 730 days.
Primary Outcome
100-day non-relapse mortality is the number of participants who died before day 100 posttransplant from causes other than relapsed disease
Interventions
- DRUG Busulfan
- DRUG G-CSF
- DRUG Leukapheresis
- PROCEDURE Stem cell reinfusion
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2006-05 |
| Est. Completion | 2009-05 |
| Phase | NA |
Why NCT00363467 stopped before completion
NCT00363467 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 3 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (100% lower).
The record links to 0 conditions, and to 4 interventions - of which Busulfan is the first listed.
NCT00363467 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00363467 about?
NCT00363467 is a clinical study titled "Busulfan Monotherapy as Conditioning for Autologous Hematopoietic Progenitor Cell Transplantation". During the pre-transplantation phase (following completion of consolidation chemotherapy), patients will begin to receive G-CSF at 10 mcg/kg twice daily; leukapheresis will also be given until a target goal for recipient body weight is obtained, or up to a maximum of 5 days. Conditioning/Preparative...
What is the current status of trial NCT00363467?
This trial is currently terminated. It is a NA study. The enrollment target is 3 participants. The study started on 2006-05. Estimated completion is 2009-05.
What interventions are being tested in trial NCT00363467?
The interventions under investigation include: Busulfan (DRUG), G-CSF (DRUG), Leukapheresis (DRUG), Stem cell reinfusion (PROCEDURE).
Who is sponsoring clinical trial NCT00363467?
This trial is sponsored by H. Lee Moffitt Cancer Center and Research Institute, which has 502 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00363467's enrollment target sits among peer trials
3 1996th of 2000 higher than 4 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia